Gynecologic Oncology - Endometrial Cancer | |
|---|---|
| Study Name | Principal Investigator |
| MK7902-001 – A Multicenter, Open-label, Randomized Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab versus Treatment of Physician’s Choice in Participants with Advanced Endometrial Cancer. Hypothesis is that combination therapy leads to improved progression-free survival. Read more. |
Sharyn Lewin, MD |
| GOG-3039 – A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced,
Recurrent or Metastatic Endometroid Endometrial Cancer. Read more. |
Sharyn Lewin, MD |
Gynecologic Oncology - Ovarian Cancer | |
| Study Name | Principal Investigator |
| FIRST – A Randomized, double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer. Hypothesis is that TSR-042 and Niraparib produces a deeper response and prolonged progression-free survival. Read more. |
Sharyn Lewin, MD |
| LAE002INT2001 – An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cance Read more. |
Maria Schiavone, MD |
| IMGN853-0419 – A Phase 2, Single Arm Study of Mirvetuximab Sorvtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (PICCOLO). Read more. |
Sharyn Lewin, MD |
| IMGN853-0420 – A Multicenter, Open-label, Phase 2 Study of Carboplatin plus Mirvetuximab Soravtansine followed by Mirvetuximab Soravtansine continuation in Folate Receptor-Alpha Positive, Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Following One Prior Line of Platinum-Based Chemotherapy. For more information about this study and to inquire about eligibility, please contact the Oncology Research Program at 201-530-7934. Read more. |
Sharyn Lewin, MD |
| IMGN853-0421 – Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with Fra-high recurrent platinum-sensitive epithelial ovarian, fallopian tube,or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA). Read more. |
Sharyn Lewin, MD |
